


### IN THE CLAIMS

Please amend the claims as follows:

Claim 1 (Original): A preventive or therapeutic agent for pathological conditions caused by reduced production of erythropoietin, comprising as an active ingredient, a cyclic amine compound represented by the following formula (1):



wherein,

$R^1$ ,  $R^2$  and  $R^3$  each independently represent a hydrogen atom, a halogen atom, or hydroxy, alkyl, halogen-substituted alkyl, alkoxy, alkylthio, carboxyl, alkoxycarbonyl or alkanoyl group;

$W^1$  and  $W^2$  each independently represent N or CH;

X represents O,  $NR^4$ ,  $CONR^4$  or  $NR^4CO$ ;

$R^4$  each represents a hydrogen atom, or an alkyl, alkenyl, alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkyl, or substituted or unsubstituted heteroaralkyl group; and

l, m and n each represents a number of 0 or 1, or a salt thereof or a solvate thereof.

Claim 2 (Original): The preventive or therapeutic agent according to claim 1, wherein  $R^1$ ,  $R^2$  and  $R^3$  are each a hydrogen atom, a halogen atom, a hydroxy group, a  $C_1$ - $C_8$ -alkyl group, a halogen-substituted  $C_1$ - $C_8$ -alkyl, an alkoxy group having a  $C_1$ - $C_8$ -alkyl group, an alkylthio group having a  $C_1$ - $C_8$ -alkyl group, a carboxyl group, an alkoxycarbonyl group having a  $C_1$ - $C_6$ -alkyl group, or an alkanoyl group having a  $C_1$ - $C_6$ -alkyl group.

Claim 3 (Original): The preventive or therapeutic agent according to claim 1, wherein  $R^4$  each represents a hydrogen atom, a  $C_1$ - $C_8$ -alkyl group,  $C_3$ - $C_8$ -alkenyl group,  $C_3$ - $C_8$ -alkynyl group, substituted or unsubstituted  $C_6$ - $C_{14}$ -aryl group, substituted or unsubstituted heteroaryl group having 5- or 6-membered ring containing 1-4 nitrogen atoms, substituted or unsubstituted  $C_6$ - $C_{14}$ -aryl- $C_1$ - $C_6$ -alkyl group, or  $C_1$ - $C_6$ -alkyl group having heteroaryl group having 5- or 6-membered ring containing 1-4 nitrogen atoms.

Claim 4 (Original): The preventive or therapeutic agent according to claim 3, wherein in  $R^4$ , the substituent of an aryl group, an aryl group of aralkyl group, heteroaryl group, or heteroaryl group of heteroaralkyl group is 1-3 groups selected from the group consisting of alkyl group, alkoxy group, alkylthio group, a halogen atom, a nitro group, an amino group, an acetylamino group, trifluoromethyl group and alkylenedioxy group.

Claim 5 (Original): The preventive or therapeutic agent according to claim 1, wherein the active ingredient is

4-[N-(4-methoxyphenyl)-N-[[5-(3,4,5-trimethoxyphenyl)pyridine-3-yl]methyl]amino]-1-[[2-(3,4,5-trimethoxyphenyl)pyridine-4-yl]methyl]piperidine;


4-[N-(3,5-dimethoxyphenyl)-N-[[2-(3,4,5-trimethoxyphenyl)pyridine-4-yl]methyl]amino]-1-[[2-(3,4,5-trimethoxyphenyl)pyridine-4-yl]methyl]piperidine;

4-[N-(3,4-methylenedioxyphenyl)-N-[[2-(3,4,5-trimethoxyphenyl)pyridine-4-yl]methyl]amino]-1-[[2-(3,4,5-trimethoxyphenyl)pyridine-4-yl]methyl]piperidine;

4-[N-methyl-N-[[2-(3,4,5-trimethoxyphenyl)pyridine-4-yl]methyl]amino]-1-[[2-(3,4,5-trimethoxyphenyl)pyridine-4-yl]methyl]piperidine;

4-[N-(4-(methylthio)phenyl)-N-[[5-(3,4,5-tromethoxyphenyl)piridine-3-yl]methyl]amino]-1-[[2-(3,4,5-tromethoxyphenyl)piridine-4-yl]methyl]piperidine; or a salt thereof.

Claim 6 (Original): A preventive or therapeutic agent for anemia, comprising as an active ingredient, a cyclic amine compound represented by the following formula (1):



wherein,

$R^1$ ,  $R^2$  and  $R^3$  each independently represent a hydrogen atom, a halogen atom, or hydroxy, alkyl, halogen-substituted alkyl, alkoxy, alkylthio, carboxyl, alkoxy carbonyl or alkanoyl group;

$W^1$  and  $W^2$  each independently represent N or CH;

X represents O,  $NR^4$ ,  $CONR^4$  or  $NR^4CO$ ;

$R^4$  each represents a hydrogen atom, or an alkyl, alkenyl, alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkyl, or substituted or unsubstituted heteroaralkyl group; and

l, m and n each represents a number of 0 or 1, or a salt thereof or a solvate thereof.

Claim 7 (Original): The preventive or therapeutic agent according to claim 6, wherein  $R^1$ ,  $R^2$  and  $R^3$  are each a hydrogen atom, a halogen atom, a hydroxy group, a  $C_1$ - $C_8$ -alkyl group, a halogen-substituted  $C_1$ - $C_8$ -alkyl, an alkoxy group having a  $C_1$ - $C_8$ -alkyl group, an alkylthio group having a  $C_1$ - $C_8$ -alkyl group, a carboxyl group, an alkoxy carbonyl group having a  $C_1$ - $C_6$ -alkyl group, or an alkanoyl group having a  $C_1$ - $C_6$ -alkyl group.

Claim 8 (Original): The preventive or therapeutic agent according to claim 6, wherein  $R^4$  each represents a hydrogen atom, a  $C_1$ - $C_8$ -alkyl group,  $C_3$ - $C_8$ -alkenyl group,  $C_3$ - $C_8$ -alkynyl group, substituted or unsubstituted  $C_6$ - $C_{14}$ -aryl group, substituted or unsubstituted heteroaryl group having 5- or 6-membered ring containing 1-4 nitrogen atoms, substituted or unsubstituted  $C_6$ - $C_{14}$ -aryl- $C_1$ - $C_6$ -alkyl group, or  $C_1$ - $C_6$ -alkyl group having heteroaryl group having 5- or 6-membered ring containing 1-4 nitrogen atoms.

Claim 9 (Original): The preventive or therapeutic agent according to claim 8, wherein in  $R^4$ , the substituent of an aryl group, an aryl group of aralkyl group, heteroaryl group, or heteroaryl group of heteroaralkyl group is 1-3 groups selected from the group consisting of alkyl group, alkoxy group, alkylthio group, a halogen atom, a nitro group, an amino group, an acetylamino group, trifluoromethyl group and alkylenedioxy group.

Claim 10 (Original): The preventive or therapeutic agent according to claim 6, wherein the active ingredient is

4-[N-(4-methoxyphenyl)-N-[[5-(3,4,5-trimethoxyphenyl)pyridine-3-yl]methyl]amino]-1-[[2-(3,4,5-trimethoxyphenyl)pyridine-4-yl]methyl]piperidine;


4-[N-(3,5-dimethoxyphenyl)-N-[[2-(3,4,5-trimethoxyphenyl)pyridine-4-yl]methyl]amino]-1-[[2-(3,4,5-trimethoxyphenyl)pyridine-4-yl]methyl]piperidine;

4-[N-(3,4-methylenedioxyphenyl)-N-[[2-(3,4,5-trimethoxyphenyl)pyridine-4-yl]methyl]amino]-1-[[2-(3,4,5-trimethoxyphenyl)pyridine-4-yl]methyl]piperidine;

4-[N-methyl-N-[[2-(3,4,5-trimethoxyphenyl)pyridine-4-yl]methyl]amino]-1-[[2-(3,4,5-trimethoxyphenyl)pyridine-4-yl]methyl]piperidine;

4-[N-(4-(methylthio)phenyl)-N-[[5-(3,4,5-trimethoxyphenyl)pyridine-3-yl]methyl]amino]-1-[[2-(3,4,5-trimethoxyphenyl)pyridine-4-yl]methyl]piperidine; or a salt thereof.

Claim 11 (Original): A preventive or therapeutic agent for chronic anemia, renal anemia, aplastic anemia or pure red cell aplasia, comprising as an active ingredient, a cyclic amine compound represented by the following formula (1):



wherein,

$R^1$ ,  $R^2$  and  $R^3$  each independently represent a hydrogen atom, a halogen atom, or hydroxy, alkyl, halogen-substituted alkyl, alkoxy, alkylthio, carboxyl, alkoxycarbonyl or alkanoyl group;

$W^1$  and  $W^2$  each independently represent N or CH;

X represents O,  $NR^4$ ,  $CONR^4$  or  $NR^4CO$ ;

$R^4$  each represents a hydrogen atom, or an alkyl, alkenyl, alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkyl, or substituted or unsubstituted heteroaralkyl group; and

l, m and n each represents a number of 0 or 1, or a salt thereof or a solvate thereof.

Claim 12 (Original): The preventive or therapeutic agent according to claim 11, wherein  $R^1$ ,  $R^2$  and  $R^3$  are each a hydrogen atom, a halogen atom, a hydroxy group, a  $C_1$ - $C_8$ -alkyl group, a halogen-substituted  $C_1$ - $C_8$ -alkyl, an alkoxy group having a  $C_1$ - $C_8$ -alkyl group, an alkylthio group having a  $C_1$ - $C_8$ -alkyl group, a carboxyl group, an alkoxycarbonyl group having a  $C_1$ - $C_6$ -alkyl group, or an alkanoyl group having a  $C_1$ - $C_6$ -alkyl group.

Claim 13 (Original): The preventive or therapeutic agent according to claim 11, wherein R<sup>4</sup> each represents a hydrogen atom, a C<sub>1</sub>-C<sub>8</sub>-alkyl group, C<sub>3</sub>-C<sub>8</sub>-alkenyl group, C<sub>3</sub>-C<sub>8</sub>-alkynyl group, substituted or unsubstituted C<sub>6</sub>-C<sub>14</sub>-aryl group, substituted or unsubstituted heteroaryl group having 5- or 6-membered ring containing 1-4 nitrogen atoms, substituted or unsubstituted C<sub>6</sub>-C<sub>14</sub>-aryl-C<sub>1</sub>-C<sub>6</sub>-alkyl group, or C<sub>1</sub>-C<sub>6</sub>-alkyl group having heteroaryl group having 5- or 6-membered ring containing 1-4 nitrogen atoms.

Claim 14 (Original): The preventive or therapeutic agent according to claim 13, wherein in R<sup>4</sup>, the substituent of an aryl group, an aryl group of aralkyl group, heteroaryl group, or heteroaryl group of heteroaralkyl group is 1-3 groups selected from the group consisting of alkyl group, alkoxy group, alkylthio group, a halogen atom, a nitro group, an amino group, an acetylamino group, trifluoromethyl group and alkylenedioxy group.

Claim 15 (Original): The preventive or therapeutic agent according to claim 11, wherein the active ingredient is 4-[N-(4-methoxyphenyl)-N-[[5-(3,4,5-trimethoxyphenyl)pyridine-3-yl]methyl]amino]-1-[[2-(3,4,5-trimethoxyphenyl)pyridine-4-yl]methyl]piperidine;

4-[N-(3,5-dimethoxyphenyl)-N-[[2-(3,4,5-trimethoxyphenyl)pyridine-4-yl]methyl]amino]-1-[[2-(3,4,5-trimethoxyphenyl)pyridine-4-yl]methyl]piperidine;


4-[N-(3,4-methylenedioxyphenyl)-N-[[2-(3,4,5-trimethoxyphenyl)pyridine-4-yl]methyl]amino]-1-[[2-(3,4,5-trimethoxyphenyl)pyridine-4-yl]methyl]piperidine;

4-[N-methyl-N-[[2-(3,4,5-trimethoxyphenyl)pyridine-4-yl]methyl]amino]-1-[[2-(3,4,5-trimethoxyphenyl)pyridine-4-yl]methyl]piperidine;

4-[N-(4-(methylthio)phenyl)-N-[[5-(3,4,5-trimethoxyphenyl)pyridine-3-yl]methyl]amino]-1-[[2-(3,4,5-trimethoxyphenyl)pyridine-4-yl]methyl]piperidine; or a salt thereof.

Claims 16-30 (Canceled).

Claim 31 (Original): A method of treating pathological conditions caused by reduced production of erythropoietin, comprising administering an effective amount of a cyclic amine compound represented by the following formula (1):



wherein,

R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> each independently represent a hydrogen atom, a halogen atom, or hydroxy, alkyl, halogen-substituted alkyl, alkoxy, alkylthio, carboxyl, alkoxycarbonyl or alkanoyl group;

W<sup>1</sup> and W<sup>2</sup> each independently represent N or CH;

X represents O, NR<sup>4</sup>, CONR<sup>4</sup> or NR<sup>4</sup>CO;

R<sup>4</sup> each represents a hydrogen atom, or an alkyl, alkenyl, alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkyl, or substituted or unsubstituted heteroaralkyl group; and

l, m and n each represents a number of 0 or 1, or a salt thereof or a solvate thereof.

Claim 32 (Original): The method according to claim 31, wherein R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> are each a hydrogen atom, a halogen atom, a hydroxy group, a C<sub>1</sub>-C<sub>8</sub>-alkyl group, a halogen-

substituted C<sub>1</sub>-C<sub>8</sub>-alkyl, an alkoxy group having a C<sub>1</sub>-C<sub>8</sub>-alkyl group, an alkylthio group having a C<sub>1</sub>-C<sub>8</sub>-alkyl group, a carboxyl group, an alkoxycarbonyl group having a C<sub>1</sub>-C<sub>6</sub>-alkyl group, or an alkanoyl group having a C<sub>1</sub>-C<sub>6</sub>-alkyl group.

Claim 33 (Original): The method according to claim 31, wherein R<sup>4</sup> each represents a hydrogen atom, a C<sub>1</sub>-C<sub>8</sub>-alkyl group, C<sub>3</sub>-C<sub>8</sub>-alkenyl group, C<sub>3</sub>-C<sub>8</sub>-alkynyl group, substituted or unsubstituted C<sub>6</sub>-C<sub>14</sub>-aryl group, substituted or unsubstituted heteroaryl group having 5- or 6-membered ring containing 1-4 nitrogen atoms, substituted or unsubstituted C<sub>6</sub>-C<sub>14</sub>-aryl-C<sub>1</sub>-C<sub>6</sub>-alkyl group, or C<sub>1</sub>-C<sub>6</sub>-alkyl group having heteroaryl group having 5- or 6-membered ring containing 1-4 nitrogen atoms.

Claim 34 (Original): The method according to claim 33, wherein in R<sup>4</sup>, the substituent of an aryl group, an aryl group of aralkyl group, heteroaryl group, or heteroaryl group of heteroaralkyl group is 1-3 groups selected from the group consisting of alkyl group, alkoxy group, alkylthio group, a halogen atom, a nitro group, an amino group, an acetylamino group, trifluoromethyl group and alkylenedioxy group.

Claim 35 (Original): The method according to claim 31, wherein the active ingredient is

4-[N-(4-methoxyphenyl)-N-[[5-(3,4,5-trimethoxyphenyl)pyridine-3-yl]methyl]amino]-1-[[2-(3,4,5-trimethoxyphenyl)pyridine-4-yl]methyl]piperidine;

4-[N-(3,5-dimethoxyphenyl)-N-[[2-(3,4,5-trimethoxyphenyl)pyridine-4-yl]methyl]amino]-1-[[2-(3,4,5-trimethoxyphenyl)pyridine-4-yl]methyl]piperidine;


4-[N-(3,4-methylenedioxyphenyl)-N-[[2-(3,4,5-trimethoxyphenyl)pyridine-4-yl]methyl]amino]-1-[[2-(3,4,5-trimethoxyphenyl)pyridine-4-yl]methyl]piperidine;



4-[N-methyl-N-[[2-(3,4,5-trimethoxyphenyl)pyridine-4-yl]methyl]amino]-1-[[2-(3,4,5-trimethoxyphenyl)pyridine-4-yl]methyl]piperidine;

4-[N-(4-(methylthio)phenyl)-N-[[5-(3,4,5-trimethoxyphenyl)pyridine-3-yl]methyl]amino]-1-[[2-(3,4,5-trimethoxyphenyl)pyridine-4-yl]methyl]piperidine; or a salt thereof.

Claim 36 (Original): A method of treating anemia, comprising administering an effective amount of a cyclic amine compound represented by the following formula (1):



wherein,

$R^1$ ,  $R^2$  and  $R^3$  each independently represent a hydrogen atom, a halogen atom, or hydroxy, alkyl, halogen-substituted alkyl, alkoxy, alkylthio, carboxyl, alkoxy carbonyl or alkanoyl group;

$W^1$  and  $W^2$  each independently represent N or CH;

X represents O,  $NR^4$ ,  $CONR^4$  or  $NR^4CO$ ;

$R^4$  each represents a hydrogen atom, or an alkyl, alkenyl, alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkyl, or substituted or unsubstituted heteroaralkyl group; and

l, m and n each represents a number of 0 or 1, or a salt thereof or a solvate thereof.

Claim 37 (Original): The method according to claim 36, wherein  $R^1$ ,  $R^2$  and  $R^3$  are each a hydrogen atom, a halogen atom, a hydroxy group, a  $C_1$ - $C_8$ -alkyl group, a halogen-substituted  $C_1$ - $C_8$ -alkyl, an alkoxy group having a  $C_1$ - $C_8$ -alkyl group, an alkylthio group

having a C<sub>1</sub>-C<sub>8</sub>-alkyl group, a carboxyl group, an alkoxycarbonyl group having a C<sub>1</sub>-C<sub>6</sub>-alkyl group, or an alkanoyl group having a C<sub>1</sub>-C<sub>6</sub>-alkyl group.

Claim 38 (Original): The method according to claim 36, wherein R<sup>4</sup> each represents a hydrogen atom, a C<sub>1</sub>-C<sub>8</sub>-alkyl group, C<sub>3</sub>-C<sub>8</sub>-alkenyl group, C<sub>3</sub>-C<sub>8</sub>-alkynyl group, substituted or unsubstituted C<sub>6</sub>-C<sub>14</sub>-aryl group, substituted or unsubstituted heteroaryl group having 5- or 6-membered ring containing 1-4 nitrogen atoms, substituted or unsubstituted C<sub>6</sub>-C<sub>14</sub>-aryl-C<sub>1</sub>-C<sub>6</sub>-alkyl group, or C<sub>1</sub>-C<sub>6</sub>-alkyl group having heteroaryl group having 5- or 6-membered ring containing 1-4 nitrogen atoms.

Claim 39 (Original): The method according to claim 38, wherein in R<sup>4</sup>, the substituent of an aryl group, an aryl group of aralkyl group, heteroaryl group, or heteroaryl group of heteroaralkyl group is 1-3 groups selected from the group consisting of alkyl group, alkoxy group, alkylthio group, a halogen atom, a nitro group, an amino group, an acetylamino group, trifluoromethyl group and alkylenedioxy group.

Claim 40 (Original): The method according to claim 36, wherein the active ingredient is

4-[N-(4-methoxyphenyl)-N-[[5-(3,4,5-trimethoxyphenyl)pyridine-3-yl]methyl]amino]-1-[[2-(3,4,5-trimethoxyphenyl)pyridine-4-yl]methyl]piperidine;


4-[N-(3,5-dimethoxyphenyl)-N-[[2-(3,4,5-trimethoxyphenyl)pyridine-4-yl]methyl]amino]-1-[[2-(3,4,5-trimethoxyphenyl)pyridine-4-yl]methyl]piperidine;

4-[N-(3,4-methylenedioxyphenyl)-N-[[2-(3,4,5-trimethoxyphenyl)pyridine-4-yl]methyl]amino]-1-[[2-(3,4,5-trimethoxyphenyl)pyridine-4-yl]methyl]piperidine;

4-[N-methyl-N-[[2-(3,4,5-trimethoxyphenyl)pyridine-4-yl]methyl]amino]-1-[[2-(3,4,5-trimethoxyphenyl)pyridine-4-yl]methyl]piperidine;

4-[N-(4-(methylthio)phenyl)-N-[[5-(3,4,5-tromethoxyphenyl)pyridine-3-yl]methyl]amino]-1-[[2-(3,4,5-tromethoxyphenyl)pyridine-4-yl]methyl]piperidine; or a salt thereof.

Claim 41 (Original): A method of treating chronic anemia, renal anemia, aplastic anemia, or pure red cell aplasia, comprising administering an effective amount of a cyclic amine compound represented by the following formula (1):



wherein,

$R^1$ ,  $R^2$  and  $R^3$  each independently represent a hydrogen atom, a halogen atom, or hydroxy, alkyl, halogen-substituted alkyl, alkoxy, alkylthio, carboxyl, alkoxycarbonyl or alkanoyl group;

$W^1$  and  $W^2$  each independently represent N or CH;

X represents O,  $NR^4$ ,  $CONR^4$  or  $NR^4CO$ ;

$R^4$  each represents a hydrogen atom, or an alkyl, alkenyl, alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkyl, or substituted or unsubstituted heteroaralkyl group; and

l, m and n each represents a number of 0 or 1, or a salt thereof or a solvate thereof.

Claim 42 (Original): The method according to claim 41, wherein  $R^1$ ,  $R^2$  and  $R^3$  are each a hydrogen atom, a halogen atom, a hydroxy group, a  $C_1$ - $C_8$ -alkyl group, a halogen-

substituted C<sub>1</sub>-C<sub>8</sub>-alkyl, an alkoxy group having a C<sub>1</sub>-C<sub>8</sub>-alkyl group, an alkylthio group having a C<sub>1</sub>-C<sub>8</sub>-alkyl group, a carboxyl group, an alkoxycarbonyl group having a C<sub>1</sub>-C<sub>6</sub>-alkyl group, or an alkanoyl group having a C<sub>1</sub>-C<sub>6</sub>-alkyl group.

Claim 43 (Original): The method according to claim 41, wherein R<sup>4</sup> each represents a hydrogen atom, a C<sub>1</sub>-C<sub>8</sub>-alkyl group, C<sub>3</sub>-C<sub>8</sub>-alkenyl group, C<sub>3</sub>-C<sub>8</sub>-alkynyl group, substituted or unsubstituted C<sub>6</sub>-C<sub>14</sub>-aryl group, substituted or unsubstituted heteroaryl group having 5- or 6-membered ring containing 1-4 nitrogen atoms, substituted or unsubstituted C<sub>6</sub>-C<sub>14</sub>-aryl-C<sub>1</sub>-C<sub>6</sub>-alkyl group, or C<sub>1</sub>-C<sub>6</sub>-alkyl group having heteroaryl group having 5- or 6-membered ring containing 1-4 nitrogen atoms.

Claim 44 (Original): The method according to claim 43, wherein in R<sup>4</sup>, the substituent of an aryl group, an aryl group of aralkyl group, heteroaryl group, or heteroaryl group of heteroaralkyl group is 1-3 groups selected from the group consisting of alkyl group, alkoxy group, alkylthio group, a halogen atom, a nitro group, an amino group, an acetylamino group, trifluoromethyl group and alkylenedioxy group.

Claim 45 (Original): The method according to claim 41, wherein the active ingredient is

4-[N-(4-methoxyphenyl)-N-[[5-(3,4,5-trimethoxyphenyl)pyridine-3-yl]methyl]amino]-1-[[2-(3,4,5-trimethoxyphenyl)pyridine-4-yl]methyl]piperidine;

4-[N-(3,5-dimethoxyphenyl)-N-[[2-(3,4,5-trimethoxyphenyl)pyridine-4-yl]methyl]amino]-1-[[2-(3,4,5-trimethoxyphenyl)pyridine-4-yl]methyl]piperidine;

4-[N-(3,4-methylenedioxyphenyl)-N-[[2-(3,4,5-trimethoxyphenyl)pyridine-4-yl]methyl]amino]-1-[[2-(3,4,5-trimethoxyphenyl)pyridine-4-yl]methyl]piperidine;

4-[N-methyl-N-[[2-(3,4,5-trimethoxyphenyl)pyridine-4-yl]methyl]amino]-1-[[2-(3,4,5-trimethoxyphenyl)pyridine-4-yl]methyl]piperidine;

4-[N-(4-(methylthio)phenyl)-N-[[5-(3,4,5-trimethoxyphenyl)pyridine-3-yl]methyl]amino]-1-[[2-(3,4,5-trimethoxyphenyl)pyridine-4-yl]methyl]piperidine; or a salt thereof.